JPRN-jRCT2080223375招募中3 期
A Phase 3, Long-Term, Open-Label Safety Study of LY2951742 (Galcanezumab) in Japanese Patients with Migraine
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 <= 65age old（—）
- 性别
- All
入选标准
- •Patients are 18 to 65 years of age
- •- For Episodic Migraine participants: Participants who completed the treatment period of Galcanezumab Placebo-Controlled Study.
- •- Have a diagnosis of chronic migraine as defined by International Headache Society (IHS) International Classification of Headache Disorders (ICHD)-3 beta guidelines (1.3) (ICHD-3 2013).
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
Evaluation of long term safety of LY2951742 in Patients with MigraineEpisodic or chronic migraine headacheEUCTR2015-001884-38-HUEli Lilly and Company312
进行中（未招募）
1 期
Evaluation of long term safety of LY2951742 in Patients with MigraineEUCTR2015-001884-38-BEEli Lilly and Company312
进行中（未招募）
1 期
Evaluation of long term safety of LY2951742 in Patients with MigraineEpisodic or chronic migraine headacheEUCTR2015-001884-38-FREli Lilly and Company270
招募中
3 期
A 52-Week, Open-Label, Long-Term Safety Study of LY2189265 in Combination With Monotherapy of Oral Antihyperglycemic Medications in Patients With Type 2 Diabetes MellitusType 2 Diabetes MellitusJPRN-jRCT2080221664Eli Lilly Japan K.K.
尚未招募
3 期
An open-label, phase 3 study of the safety of the O’Neil Long Acting Naltrexone Implant treatment for substance dependenceACTRN12609000682246Go Medical Industries Inc500